Methods of treating hot flashes with formulations for transdermal or transmucosal application
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
A61K-031/56
출원번호
US-0584302
(2012-08-13)
등록번호
US-8647665
(2014-02-11)
발명자
/ 주소
Simes, Stephen M.
Lehman, Leah M.
출원인 / 주소
Antares Pharma IPL AG
대리인 / 주소
Winston & Strawn LLP
인용정보
피인용 횟수 :
1인용 특허 :
135
초록▼
The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effecti
The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about 0.45 to about 0.6 mg of estrogen per day. The amount of estrogen which is administered produces an estimated nominal daily estrogen dose in a subject undergoing treatment of from about 10 to about 15 micrograms, and a serum estradiol level of between about 25 pg/ml to about 50 pg/ml. The preferred formulations are substantially free of malodorous, and irritation causing long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
대표청구항▼
1. A method for treating hot flushes, comprising administering to a patient in need thereof a daily dosage for a period of at least 5 weeks of 0.1 g to 1.0 g of a topical or transmucosal formulation comprising: from 0.01% to 0.5% by weight of estrogen,from 20% to 65% by weight of a C2-C4 alkanol,fro
1. A method for treating hot flushes, comprising administering to a patient in need thereof a daily dosage for a period of at least 5 weeks of 0.1 g to 1.0 g of a topical or transmucosal formulation comprising: from 0.01% to 0.5% by weight of estrogen,from 20% to 65% by weight of a C2-C4 alkanol,from 1% to 15% by weight of a polyalcohol, wherein the polyalcohol is elected from the group consisting of propylene glycol, butylene glycol, hexylene glycol and ethylene glycol;from 1% to 15% by weight of a permeation enhancer, wherein the permeation enhancer is selected from the group consisting of: diethylene glycol monoethyl ether and diethylene glycol monomethyl ether';from 0.05% to about 4% by weight of a gelling agent,from 0.05% to 1% of a neutralizing agent;from 20% to 65% of water;wherein the amount of formulation and percentage weight of estrogen in the formulation are selected to apply a daily dosage from 0.45 mg to about 0.6 mg per day of estrogen. 2. The method of claim 1, wherein the polyalcohol and permeation enhancer are present in a weight ratio of 1.25:1 to 1.2:1. 3. The method of claim 1, wherein the daily dosage is administered by applying an amount of about 0.75 g to about 1 g of the formulation. 4. The method of claim 1, wherein the formulation is applied in an amount of from about 0.85 g to about 0.9 g with the estrogen present in an amount of about 0.06% by weight of the formulation, and wherein the polyalcohol is polypropylene glycol, the alkanol is selected from the group consisting of ethanol, isopropanol and n-propanol, and the permeation enhancer is diethylene glycol monoethyl ether. 5. The method of claim 1, wherein the subject is female and the amount of estradiol which is administered daily is effective to produce a serum estradiol level in the subject of between about 25 pg/ml to about 50 pg/ml, and wherein the estimated nominal daily estrogen dose provided by the formulation is from about 10 to about 15 micrograms. 6. The method of claim 1, wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters in order to avoid undesirable odor and irritation effects caused by such compounds during use of the formulation. 7. The method of claim 1, wherein the estrogen is selected from the group consisting of 17 beta-estradiol, estradiol, estradiol benzoate, estradiol 17 beta-cypionate, estriol, estrone, ethinyl estradiol, mestranol, moxestrol, mytatrienediol, polyestradiol phosphate, quinestradiol, quinestrol, and any combination thereof. 8. The method of claim 1, wherein the gelling agent is selected from the group consisting of carbomer, carboxyethylene, polyacrylic acid, cellulose derivatives, ethylcellulose, hydroxypropylmethylcellulose, ethylhydroxyethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, natural gums, arabic, xanthan, guar gums, alginates, polyvinylpyrrolidone derivatives, polyoxyethylene polyoxypropylene copolymers, chitosan, polyvinyl alcohol, pectin, and veegum; the buffering agent is selected from the group consisting of carbonate buffers, citrate buffers, phosphate buffers, acetate buffers, hydrochloric acid, lactic acid, tartric acid, diethylamine, triethylamine, diisopropylamine, tetrahydroxypropylethylendiamine, and aminomethylamine; and the sequestering agent is edetic acid. 9. The method of claim 1, wherein the formulation is in the form of a gel, lotion, cream, spray, aerosol, ointment, emulsion, suspension, liposomal system, lacquer, or non-occlusive dressing. 10. The method of claim 1 wherein the formulation has the following composition: Estradiol0.01%-0.5%Carbomer 9401.2%Triethanolamine (adjust to pH 5.9)0.4%Alcohol46.28% Propylene glycol 6%Diethylene glycol monoethyl ether 5%Disodium EDTA0.06% Ion Exchange Purified Water q. ad.100%. 11. The method of claim 1, wherein the formulation has the following composition: Estradiol0.06%Ethanol, Dehydrated46.28% Propylene Glycol 6%Diethylene glycol monoethyl ether 5%Carbomer 9401.20%Triethanolamine0.35%Ion Exchange Purified Water q. ad. 100%.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (135)
Piasco Alain,FRX ; Lafay Jean,FRX ; Delansorne Remi,FRX ; Paris Jacques,FRX ; Pascal Jean-Claude,FRX, 19-nor-pregnene derivatives and pharmaceuticals containing such derivatives.
David Scott Dunlop ; Susan Marie Guskey ; Vicente Eduardo Leyba VE; Douglas Allan Royce, Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers.
Hartell, Mark G.; Bhattacharjee, Apurba K.; Hicks, Rickey P.; VanHamont, John E.; Milhous, Wilbur K., Artemisinins with improved stability and bioavailability for therapeutic drug development and application.
Carrara,Dario; Porto,Gabriel; Rodriguez,Jorge, Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels.
Kanios David P. ; Gentile Joseph A. ; Mantelle Juan A. ; Sablotsky Steven, Compositions and methods for topical administration of pharmaceutically active agents.
Kenneth B Kirby ; Berno I. R. Pettersson, Jr., Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof.
Oettel Michael,DEX ; Golbs Siegfried,DEX ; Dittgen Michael,DEX ; Timpe Carsten,DEX ; Graser Thomas,DEX ; Hubler Doris,DEX, Compound preparation for the treatment of hypogonadal men and men with hypophyseal diseases.
Stella Valentino J. (Lawrence KS) Rajewski Roger (Lawrence KS), Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof.
Reed Barry Leonard,AUX ; Morgan Timothy Matthias,AUX ; Finnin Barrie Charles,AUX, Dermal penetration enhancers and drug delivery systems involving same.
Iles Martin C. (7 Cartwright Drive Shaw ; Swindon ; Wiltshire GBX) Atherton Angela D. (170 ; Windsor Drive Chelsfield ; Orpington ; Kent GBX) Copping Neil M. (8 Lautrec Way Haydon Hill ; Aylesbury ; , Freeze-dried dosage forms and methods for preparing the same.
Al-Razzak Laman A. ; Constantinides Panayiotis Pericleous ; Kaul Dilip ; Lipari John M. ; McChesney-Harris Lisa L. ; Abdullah Bashar Y., Hydrophilic binary systems for the administration of lipophilic compounds.
Wong Ooi (Fremont CA) Farinas Kathleen C. (San Francisco CA) Cleary Gary W. (Menlo Park CA) Chiang Chia-Ming (Foster City CA) Xia Jun (Redwood City CA), Method and device for providing nicotine replacement therapy transdermally/transbuccally.
Campbell Patricia S. (Palo Alto CA) Enscore David J. (Sunnyvale CA) Gale Robert M. (Los Altos CA) Kaufman Arnold (Palo Alto CA), Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix.
Osborne James L. (2365 Thompson Ct. Mountain View CA 94043) Nelson Melinda K. (1127 Hollenbeck Sunnyvale CA 94087) Enscore David J. (18291 Montpere Way Saratoga CA 95070) Yum Su I. (1021 Runnymead Ct, Method of administering nicotine transdermally.
Young James W. ; Brandt Steven, Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+).
Aberg Gunnar (Westborough MA) McCullough John R. (Worcester MA), Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin.
Berner Bret (Scarsdale NY) Ebert Charles (Salt Lake City UT) Mazzenga Gerard C. (New City NY) Otte John H. (Monsey NY), Mixed solvent mutually enhanced transdermal therapeutic system.
Kasting Gerald B. (Wyoming OH) Massaro Ellen R. (Cincinnati OH) Smith Ronald L. (West Chester OH) Snyder William E. (Cincinnati OH), Penetrating topical pharmaceutical compositions.
Patel Dinesh C. (Murray UT) Chang Yunik (Lakewood NJ), Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols.
Rhodes John,GBX ; Rhodes Peter,GBX ; Evans Brian Kenneth,GBX, Pharmaceutical products containing a complex of an amide-type local anesthetic and a polyacrylate.
Punto Louis L. (Northport NY) Zecchino Jules R. (Closter NJ) Lentini Peter J. (Glen Oaks NY), Self-tanning cosmetic compositions and methods of using the same.
Chiang Chia-Ming (Foster City CA) Cleary Gary W. (San Mateo CA), Skin permeation enhancer compositions, and methods and transdermal systems associated therewith.
Chiang Chia-Ming (Foster City CA) Cleary Gary W. (San Mateo CA), Skin permeation enhancer compositions, and methods and transdermal systems associated therewith.
Stttgen Gnter (Berlin DEX) Schaefer Hans (Berlin DEX), Topical combinations of an a
상세보기
Sato ; deceased Toshiya (late of Kanagawa JPX by Kuniko Sato ; legal representative) Ishida Kenya (Kanagawa JPX), Topical composition for treating acne vulgaris.
Lipp Ralph,DEX ; Gunther Clemens,DEX ; Riedl Jutta,DEX ; Tauber Ulrich,DEX, Transdermal therapeutic systems that contain sex steroids and dimethyl isosorbide.
Quan Danyi (Salt Lake City UT) Deshpanday Ninad A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT), Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
Quan Danyi ; Deshpanday Ninad A. ; Venkateshwaran Srinivasan ; Ebert Charles D., Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.